Kazunori Fujitaka
Kazunori Fujitaka publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Lung Cancer Treatments and Mutations and Lung Cancer Diagnosis and Treatment.
- World rank
- #3,319,045 of 7,710,434 ranked researchers
- Rank in Japan
- #78,769 of 383,136
- Works
- 246
- Citations
- 2.9k
- Citations per work
- 11.8
What does Kazunori Fujitaka research?
Kazunori Fujitaka's work is mostly in Medicine (65%), Biochemistry, Genetics and Molecular Biology (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences16065.0%
- Medicine16065.0%
- Everything else7028.6%
- Life Sciences166.4%
- 1Pulmonary and Respiratory Medicine39% of their works
- 2Oncology15% of their works
- 3Molecular Biology6% of their works
- 4Physiology4% of their works
- 5Cardiology and Cardiovascular Medicine4% of their works
- 6Epidemiology3% of their works
Research topics
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Lung Cancer Research Studies
- Venous Thromboembolism Diagnosis and Management
- Advanced Glycation End Products research
Which keywords describe Kazunori Fujitaka's research?
The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Fibrosis, Idiopathic Pulmonary Fibrosis, ALK Inhibitors, EGFR Mutations, Chemotherapy and Diagnosis.
- HMGB1
- Venous Thromboembolism
- Small-Cell Lung Cancer
- spirometry
- PD-1 and PD-L1
- Lung Cancer
- Diagnosis
- EGFR Mutations
- Idiopathic Pulmonary Fibrosis
- Targeted Therapy
- Clinical Trials
- Fibrosis
- ALK Inhibitors
- Chemotherapy
- CT Screening
- Immune Checkpoint Blockade
- COPD
- Genomic Profiles
- Antithrombotic Therapy
- Advanced Glycation End Products
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 20 words, with their numbers
- Clinical Trials762 topics
- Targeted Therapy762 topics
- Fibrosis661 topic
- Idiopathic Pulmonary Fibrosis661 topic
- ALK Inhibitors571 topic
- EGFR Mutations571 topic
- Chemotherapy462 topics
- Diagnosis332 topics
- CT Screening271 topic
- Lung Cancer271 topic
- Immune Checkpoint Blockade231 topic
- PD-1 and PD-L1231 topic
- COPD201 topic
- spirometry201 topic
- Genomic Profiles191 topic
- Small-Cell Lung Cancer191 topic
- Antithrombotic Therapy131 topic
- Venous Thromboembolism131 topic
- Advanced Glycation End Products121 topic
- HMGB1121 topic
Where does Kazunori Fujitaka work?
Kazunori Fujitaka's main affiliation in the publication record is Hiroshima University, Japan.
How many publications and citations does Kazunori Fujitaka have?
OpenAlex counts 246 works and 2,910 citations for Kazunori Fujitaka, an h-index of 29, ranking #3,319,045 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Kazunori Fujitaka. Posts are plain text and can be reported.